Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Moves Closer To Reducing HTA Discount Rate For First Time In Decades

Executive Summary

The pharmaceutical industry body Medicines Australia has welcomed an advisory committee’s recommendation on reducing the 5% discount rate that has been used in health technology assessments for 30 years, although it would have liked to see a bigger reduction and to have it implemented more quickly.

You may also be interested in...



Australian HTA Consults On Discount Rate

PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.

France: Repatriating Drug Production Among Actions In ‘Roadmap’ For Tackling Shortages

The key themes of France’s latest initiative on shortages are repatriating the production of certain essential medicines and their active substances, earlier detection of potential supply problems, and more effective and transparent communications with all actors in the supply chain.

EMA Addresses Need For Guideline On Antivirals & MAbs For COVID-19

New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel